Investors Overview

About Us

Bioblast Pharma is a publicly traded, clinical-stage biotechnology company (NASDAQ - "ORPN") committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.

Our therapeutic platforms are based on deep understanding of the disease-causing biological processes, and can potentially offer solutions for several diseases that share the same biological pathology.

Given the interest in the scientific and medical community regarding alternative therapeutic uses of our lead drug candidate, trehalose 90mg/mL IV solution, Bioblast has decided to postpone work on our other therapeutic platforms and to concentrate internal development efforts exclusively on trehalose.

The company is led by a management team experienced in the development and commercialization of disease therapeutics.

Read More

Events

There are currently no events scheduled.

More Events

News

Bioblast Pharma Reports Second Quarter 2016 Financial ResultsAugust 25, 2016
TEL AVIV, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today annou... 
Bioblast Pharma Updates Corporate PlansJune 09, 2016
Trehalose Phase 2b Trial in Oculopharyngeal Muscular Dystrophy (OPMD)  On Track to Commence During the Second Half of 2016  Focus On Trehalose As a Potential Platf... 
Bioblast Pharma Reports First Quarter 2016 Financial ResultsMay 25, 2016
NEW HAVEN, Conn., May 25, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announ... 
More News